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Abstract
Objectives This study aimed to investigate the effects of adding
adjunct mechanical imaging to mammography breast screening.
We hypothesized that mechanical imaging could detect in-
creased local pressure caused by both malignant and benign
breast lesions and that a pressure threshold for malignancy could
be established. The impact of this on breast screening was in-
vestigated with regard to reductions in recall and biopsy rates.
Methods 155 women recalled from breast screening were in-
cluded in the study, which was approved by the regional eth-
ical review board (dnr 2013/620). Mechanical imaging read-
ings were acquired of the symptomatic breast. The relative
mean pressure on the suspicious area (RMPA) was defined
and a threshold for malignancy was established.
Results Biopsy-proven invasive cancers had a median RMPA
of 3.0 (interquartile range (IQR) = 3.7), significantly different
from biopsy-proven benign at 1.3 (IQR = 1.0) and non-
biopsied cases at 1.0 (IQR = 1.3) (P < 0.001). The lowest
RMPA for invasive cancer was 1.4, with 23 biopsy-proven
benign and 33 non-biopsied cases being below this limit.
Had these women not been recalled, recall rates would have
been reduced by 36% and biopsy rates by 32%.
Conclusions If implemented in a screening situation, this may
substantially lower the number of false positives.
Key Points
•Mechanical imaging is used as an adjunct to mammography
in breast screening.
• A threshold pressure can be established for malignant breast
cancer.
• Recalls and biopsies can be substantially reduced.
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Introduction
Mammography screening recalls
Mammography is the premier means of breast cancer screen-
ing worldwide and is, despite some criticism, considered an
effective way of reducing breast cancer mortality [1–3].
Screening incurs significant expenses for the healthcare sys-
tem [4–6]. According to the European Guidelines for Quality
Assurance in Mammography Screening [7] recall rates should
be 3–5% (7% in the prevalence round). A recent publication
reported recall rates in three countries – the USA, Norway and
Spain – to be 9.1%, 3.2% and 4.2%, respectively [8]. The rate
of screening detected cancers was 0.4–0.55% per screening
round, meaning that about 90% of recalls are false positives.
Another study estimated that of women screened biennially
starting at the age of 50 years, 20%would have a false positive
result at least once before the age of 68 years [9]. False pos-
itives put a substantial economic demand on the healthcare
system, and subject women to considerable anxiety and other
negative psychosocial consequences [10–13].
False positives can be divided into two groups: benign
findings and normal tissue. The first group consists of several
types of benign lesions – cysts, fibroadenoma, papillomas etc.,
while the second is normal tissue which appears suspicious,
e.g. over-projection of fibroglandular strands at different
depths.
Other breast imaging modalities
Breast tomosynthesis has the potential to complement and/or
replace digital mammography in standard screening practice.
European prospective studies and US retrospective studies
have investigated its impact on breast cancer screening
[14–23]. Three prospective studies – STORM [14], OTST
[18] and MBTST [23] – have shown superior cancer detec-
tion. Concerning recall rates, the prospective studies show an
increase, while the retrospective studies generally show a de-
crease [15–17, 19–22]. Spectral mammography is another al-
ternative, with a recent study demonstrating its ability to dis-
tinguish between cystic and solid lesions [24].
In addition to mammography, ultrasonography is often
used in the work-up of recalled women. It is effective at dif-
ferentiating malignant and benign findings [25–27]. General
screening with ultrasound is not implemented due to a lack of
cost-effectiveness, related to examination time and the need
for a trained operator to carry out the procedure, and the high
false-positive rate [28–30]. The J-START trial investigated
ultrasonography as an adjunct to mammography in screening
on 72,988 women, and found it to be effective for detecting
more cancers at an earlier stage, but did not assess its econom-
ic efficacy [31–33]. Various automatic and semi-automatic
ultrasound systems exist, but their performance in screening
has not been established [34].
Mechanical imaging
There are marked differences in the mechanical properties of
various types of breast tissue [35]. The modulus of elasticity,
or Young’s modulus – for an elastic material subject to a cer-
tain degree of deformation – relates the stress (pressure
exerted on the material) to the strain (relative deformation of
the material), i.e. the greater the elastic modulus, the stiffer the
material. The tissues in the human breast are non-linearly
elastic, which means that the value of the elastic modulus
increases with the level of strain.
Mechanical imaging (MI) is defined as the practice of
deforming tissue and measuring the resulting distribution of
pressure – or stress field – using pressure sensors [36, 37]. The
measured pressures on different locations provide information
about the underlying elastic modulus of the deformed tissue,
as the pressure will be proportionately higher with increasing
elastic modulus. As there is a considerable difference in elastic
modulus between various types of benign and malignant
breast tissue there is thus the possibility of using this technique
to differentiate such structures. Notably, according to
Krouskop et al., malignant tumours have a substantially great-
er elastic modulus than other tissues, especially so at higher
degrees of deformation (strain) [35]. Egorov et al. described a
sensitivity of 91% and specificity of 87% for a form of MI of
the breast [38, 39]. This method uses a handheld probe –
similar in appearance to an ultrasound probe – which is man-
ually moved over the parts of the breast being examined.
Our group has in earlier studies used a Tekscan Iscan force
sensing resistor system (Tekscan Inc., South Boston, MA,
USA) consisting of pressure sensors attached to the compres-
sion plate of a mammography device to obtain pressure read-
ings of the compressed breast [40–43]. In one study we inves-
tigated the pressure over cancerous lesions, finding a signifi-
cant difference in pressure over the lesions compared to the
background pressure [43]. The use of pressure sensors during
imaging at mammography screening, giving real-time pres-
sure reading in conjunction with the screening images, has
not previously been investigated.
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Aims
This study aimed to use MI to investigate if it is possible to
differentiate malignant lesions from benign and normal find-
ings in the female breast, and what effect using such a proce-
dure as an additional modality to screening mammography
would have on recall rates.
Methods and materials
Study design
The experimental setup used MI on women recalled from
screening. A ‘minimum threshold for malignancy’ was
established by correlation of local pressure with pathology.
From this, the impact of adding adjunct MI to screening was
estimated in terms of reduced recall rates, assuming that the
radiologist would recommend recall based on the screening
mammogram and mark the location of the suspicious finding,
with an actual recall assumed to be made only if the local
pressure on that feature exceeded the threshold for
malignancy.
Data acquisition
An improvised MI device was created by affixing two Iscan
model 9801 sensors to the inferior side of the compression
paddle of a MAMMOMAT Inspiration mammography device
(Siemens Healthcare GmbH, Erlangen, Germany). These sen-
sors have been used in our previous studies, and their perfor-
mance in similar situations has been investigated [44, 45].
Each sensor consists of 96 individual sensor elements, arrayed
in six rows of 16. Each sensor element is a square with a side
of 12.7 mm and a total thickness of roughly 0.16 mm (Fig. 1).
The sensors were positioned in contact with the juxta-
thoracic edge of the compression paddle, so they could
measure pressure as closely as possible to the chest wall. To
maximize breast coverage, for the cranio-caudal (CC) projec-
tion the sensors were centred on the paddle, while on the
mediolateral oblique (MLO) projection they were positioned
in contact with the appropriate axillary edge (Fig. 2). The
projection used was individually determined based on which
one was considered to be most likely to have pressure distrib-
uted to the suspicious area, with CC preferred in unclear cases.
MI was carried out subsequent to mammography of the
recalled woman. The breast was positioned as normal for the
corresponding mammography projection and compressed to
the standard level of compression. Pressure readings from
both sensors were acquired in sequence. A low dose mammo-
gram (5 mAs) of the breast with attached sensors was also
acquired, in order to be able to match pressure data with ra-
diological findings.
Data analysis
The centre of each suspicious feature was determined by com-
paring the clinical mammogram of each case with the corre-
sponding minimal-dose mammogram with included sensors.
The mean pressure of the 3 × 3 sensor elements centred on
each feature was measured and then normalized by the mean
pressure over the breast, defined as the mean pressure of all
sensor elements completely covered by the breast as deter-
mined by inspecting the minimal-dose mammogram. This
value was referred to as RMPA (relative mean pressure over
lesion area). For women having multiple suspicious areas, the
Fig. 1 A Tekscan Iscan 9801 pressure sensor employed in the study.
Each strip consists of four sensor elements. The electrical impedance of
the sensor elements decreases when subject to pressure
Fig. 2 Illustration of sensor positioning on the compression paddle. The
two sensor matrices were positioned adjacent to each other to cover as
much of the compression paddle as possible. For the craniocaudal (CC)
view, the sensors were centred on the juxta-thoracic edge of the compres-
sion paddle (right). For the mediolateral oblique (MLO) view, sensors
were instead placed in contact with the appropriate axillary edge of the
paddle, in order to cover axillary tissue (left)
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highest individual RMPAwas used. The column of the sensor
matrix closest to the chest wall, and for MLO-cases the row
closest to the armpit, were excluded because of the pressure
values in these areas frequently being saturated.
Wilcoxon’s rank sum test was used to compare the median
values of groups, with significant differences defined at the
95% confidence level. Descriptive statistics given in the
Results section are thus the median and interquartile range
(IQR) of various groups of data.
Study population
Enrolled women were from those participating in the Swedish
national breast screening program at Skåne University
Hospital in Malmö, between 27 February 2014 and 11
March 2015. The study was approved by the regional ethical
review board (dnr 2013/620). A notification that theymight be
asked to take part in a study involving pressure measurements
was included in the recall notification.
A number of time slots were set-aside each week for study
patients depending on the availability of the researchers and
the needs of the clinic. All recalled women scheduled for those
time slots received additional written and oral information
about the study upon arrival and were asked to provide in-
formed consent to participate in the study. The scheduling of
examinations deliberately excluded stereotactic biopsies, in
order not to interrupt the clinical workflow. In addition, non-
Swedish speaking women as well as women with breast im-
plants were excluded.
The study involved 155 women. Screening notes and pri-
mary radiological reports were used to identify the suspicious
areas that warranted recall of the woman. In unclear cases, all
women were considered to have at least one suspicious fea-
ture: (1) if no specific area was mentioned as the reason for
recall but this was still obvious from later clinical mammo-
grams and/or other sources, or (2) if no suspicious area could
be identified. If multiple suspicious areas were identified, the
one with the highest RMPAwas used.
Validation of measurements
In order to identify potentially inconclusive readings, all MI-
readings were validated based on five criteria before determi-
nation of RMPA:
1. Technical problems with sensors, measurement electron-
ics and/or the measurement software
2. Feature not in the field-of-view in the projection in which
pressure measurements were acquired
3. Feature located in an area with very high or saturated
pressure values, i.e. on the pectoral muscle or on the col-
umn of pressure sensors closest to the chest wall
4. Feature not present on recall
5. Very low or no pressure on the location of the feature, i.e.
the feature being either in the periphery of the breast –
where there is no pressure as there is no contact with the
compression paddle – or in a part of the breast lacking
compression due to unfavourable pressure distribution.
Any woman meeting one of these criteria was automatical-
ly included in the recalled group, just as if the RMPA had been
higher than the recall threshold as malignancy could not be
ruled out based on MI.
Results
Biopsies were carried out on 71 women, of which 50 were
benign, representing either benign lesions or normal tissue.
These are labelled biopsy-proven benign. The remaining 84
cases did not warrant a biopsy and were thus very likely (but
not certainly) benign. These are labelled as other benign. The
biopsy-proven cancers are labelled as such (Table 1).
For a number of women no useful MI-readings could be
acquired, according to the five criteria described above
(Table 2). The conclusive cases consisted of: 14 biopsy-proven
malignant lesions (11 IDC, ILC or tubular, two DCIS (DCIS
only, no other signs of malignancy, i.e. discernible mass) and
one non-Hodgkin’s lymphoma), 43 biopsy-proven benign, 53
other benign.
For biopsy-proven benign features RMPA values were
found to be 1.3 (IQR = 1.0), which was not significantly dif-
ferent (P = 0.63) from the RMPA values for other benign fea-
tures, 1.0 (IQR = 1.1). After excluding the remaining cases of
DCIS (2) and non-Hodgkin’s (1) lymphoma the value became
3.0 (IQR = 3.7) for biopsy-proven cancers. The two DCIS
cases had RMPA values of 0.6 and 0.9, respectively, while
the single non-Hodgkin’s lymphoma case had a value of 0.7.
The RMPA of the cancer group was significantly different
from both the biopsy-proven benign cases (P < .0001) and
other benign cases (P < .0001).
Including all malignant cases, the minimum RMPA for
malignancy was 0.6, while excluding DCIS and non-
Hodgkin’s lymphoma put the minimum threshold at 1.4
(Fig. 3). Using the lower level, this would put 18 benign
cases below the recall limit, nine of which were biopsied.
With the higher limit, 56 benign cases were below the
limit, 23 of which were biopsied. With the original popu-
lation of 155 women, of which 71 were biopsied, this
would be equivalent to a reduction of recall rates by 12%
and 36%, respectively, with the biopsy rates likewise de-
creasing by 13% and 32%, respectively (Fig. 4). All wom-
en with inconclusive MI results would be recalled as nor-
mal. Examples of MI cases (malignant and benign) are
shown in Fig. 5.
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Discussion
The results suggest a definable lower RMPA threshold for
malignant breast cancer, below which all suspicious findings
were benign. This is consistent with our hypothesis and earlier
results in the field. The cancer material is rather small, which
necessitates a larger study to establish the method’s applica-
bility. That said, results show a substantial difference between
malignant and benign cases. Though it is prudent to use a
somewhat lower threshold, the benefits – both for the
healthcare system and for patient comfort and compliance –
would still be considerable. A reduction of recalls by almost
40% is similar to the most optimistic clinical appraisals of the
effect of breast tomosynthesis screening [15, 16, 21, 22]. MI
could be used alongside breast tomosynthesis as well as mam-
mography, though the effects need to be investigated. Erhard
et al. investigated using spectral mammography to avoid re-
calls by distinguishing fluid-filled cysts from malignant le-
sions [24]. If all recalls of fluid-filled cysts could be avoided,
the total decrease of recalls would be 20%, with less than one
missed cancer per 625 correctly identified cysts. A similar
analysis of the MI system would be valuable in the future.
The calculations of recall and biopsy rate reductions as-
sumed that all cases for which MI-readings could not be used
in the final analysis would be recalled as indicated by screen-
ing mammography. The estimated reductions are thus conser-
vative. In a screening implementation, the number of
inconclusive measurements would probably be substantially
lower. Technical problems were unavoidable with the basic
prototype setup used in the study, with some cases excluded
due to poor pressure over the suspicious feature likely
resulting from this. The 11 cases that were inconclusive be-
cause of the suspicious feature not being present on MI could
also presumably have been avoided. Other inconclusive mea-
surements are likely unavoidable to some extent, as regardless
of positioning, tumours in certain locations might never have
substantial pressure applied to them due to the structure of the
breast and the design of the compression paddle. This could be
mitigated by performing MI in both MLO and CC with a
greater chance of the suspicious feature being adequately
compressed in at least one projection.
The amount of inconclusive readings (29% overall) was
similar for malignant cases (33%) and benign cases (28%),
which implies that there was no bias. There was a trend to-
wards more BI-RADS category B and less category C women
among inconclusive cases, though this was not statistically
significant (Fig. 6). Biopsied cases were less likely to be in-
conclusive than non-biopsied ones (20% vs. 37%). One crite-
rion was that the suspicious finding did not present on recall,
which partly explains this, as these were of course all in the
non-biopsied group. Having MI data available for those cases
in particular would be very valuable, as they are very likely to
amount to over-projection of tissue.
Stereotactic biopsies are primarily performed on women
with suspicious microcalcifications. This might make the
number of DCIS cases disproportionately low.
One obstacle to the system’s clinical implementation is the
sensors, which are clearly visible on the mammogram and
impair image quality. To be effective, radio-translucent sen-
sors are likely needed, or alternatively some form of subtrac-
tion imaging.
In the current study we only investigated effects on screening
specificity, i.e. trying to reduce recalls. The mechanical imaging
data was evaluated after identifying suspicious findings on
mammography, to filter out false positives. It would also be of
great value to investigate effects on sensitivity, i.e. using me-
chanical imaging to find lesions obscured on mammography.
Table 1 Overview of the









Total 21 50 84 155
Total inconclusive 7 7 31 45
Technical problems 2 4 5 11
Outside field-of-view 2 2 7 11
On pectoral muscle/chest wall 0 0 3 3
Not present at recall 0 0 9 9
Low pressure on suspicious area 3 1 7 11
Table 2 Description of biopsy results for suspicious biopsied findings
Biopsy results Number
Malignant (biopsy-proven malignant) 21
Invasive ductal carcinoma 11
Invasive lobular carcinoma 5
Tubular carcinoma 1
Ductal carcinoma in situ 2
Non-Hodgkin’s lymphoma 2
Benign (biopsy-proven benign) 50
Not biopsied (other benign) 84
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Fig. 4 Overview of the effect on
recalls after taking mechanical
imaging into account; 38% of the
total number of cases do not
require recall, including 32% of
those biopsied. Note that the
inconclusive cases are included in
the total number of recalls, as MI
cannot be used to draw any
conclusions in those cases
Fig. 3 Differences in relative
mean pressure (RMPA) between
the included groups. Note that
ductal carcinoma in situ (DCIS; in
isolation, i.e. not associated with
any mass) lies close to the mean
breast pressure. There is no sig-
nificant difference between the
biopsied and non-biopsied groups
of benign lesions, though both
benign groups lie significantly
under the malignant group
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Variations in the normal pressure distribution would likely result
in an excess of false positives. Possible remedies would be to
correlate with the pressure distribution in the contralateral breast,
and also with the distribution of dense tissue and BI-RADS
density category. We intend to evaluate this in a further study
on the collected material. Also a much larger prospective study
is needed to fully investigate the method.
Boyd et al. investigated the relationship between breast
tissue stiffness and risk of cancer, with results suggesting it
to be an independent risk factor [46]. It might be that the
elevated RMPA score of a malignant lesion is indicative of
cancer not because the cancer increases local stiffness, but
because areas with high stiffness have a higher chance of
developing cancer. We speculate that cancer is more likely to
develop in high stiffness areas (associated with increased local
density) and alters stiffness both through its presence and
through reactive fibrosis. Size, type and positioning also likely
play a role, with RMPA being for example dependent on the
size of the tumour in relation to the thickness of the breast. It is
also likely that radiologically stellate and circumscribed le-
sions have different properties. In the study, all invasive breast
cancers were stellate.
The material is too small to findMI differences between the
various subtypes of invasive cancer. Ductal carcinoma in-situ
are however distinct, with both cases in the study showing a
non-elevated RMPA. This is not unexpected, as they
expressed only as microcalcifications with no associated solid
lesion. The MI system should thus be considered a screening
detection aid for suspicious masses. When faced with suspi-
cious looking clusters of microcalcifications radiologists must
be prepared to recall despite MI readings. The two non-
Hodgkin’s lymphoma in the material are a statistical anomaly.
One lesion was located in the axillary area where no MI read-
ings could be acquired, while the one located in the breast had
a low RMPA, perhaps implying properties different from in-
vasive breast cancer. Though one case would not have been
recalled using our proposed workflow, the impact of this case
on the study is not predictive of the impact of breast lympho-
mas in a screening situation.
In conclusion, there is a difference in stiffness between
malignant and benign lesions in the breast, which this study
suggests is possible to detect with MI. Implementing MI in
screening can potentially substantially lower recall and biopsy
rates. The promising results of this study warrant prospective
clinical trials.
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Fig. 5 Examples of mechanical imaging data from the study, matched
with corresponding mammogram. All three groups are represented, from
left to right: A, not biopsied, presumed benign; B, biopsied, benign; and
C, biopsied, malignant. The relative mean pressure over lesion area
(RMPA) is defined as the mean of the pressure values in the 3 × 3 sensor
elements centred on the suspicious feature, normalized by mean pressure
over the breast. Note the presence of a high pressure area outside of the
breast on the leftmost image; it is caused by wrinkling of the sensor. This
is one example of a technical problem, which in this case did not affect the
measurement
Fig. 6 Bar plots of the BI-RADS density classifications of women in-
cluded in the study. Women who had inconclusive readings are shown on
the right. There was a trend towards the inconclusive group having a
greater proportion of category B and lesser proportion of category C
breasts, though this was not significant (P = .09)
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